actavis.be Report : Visit Site

Technical data of the actavis.be

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host actavis.be. Currently, hosted in Israel and its service provider is TEVA .

the related websites

actavis.co.uk bloomberg.com actavisacademy.co.uk xpil.medicines.org.uk tqr.co.uk europages.co.uk ft.com medicines.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- pharmaceutical industries ltd. teva worldwide stock your browser does not support iframes. contact us hebrew see teva's sites around the world north america canada united states international markets argentina australia belarus brazil chile china india israel japan kazakhstan mexico peru russia singapore south africa south korea turkey ukraine uruguay uzbekistan europe europe austria belgium bosnia & herzegovina bulgaria croatia czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania macedonia netherlands norway poland portugal romania serbia slovakia slovenia spain sweden switzerland united kingdom see all see less want to find out more about teva's locations and phone numbers? visit teva worldwide ‘play more’ campaign gets kids outdoors discover more climbing high to help those in need discover more fighting antibiotic resistance with education discover more teva social impact report now available read the report helping communities stay healthy discover more teva deploys 2d barcode to fight counterfeit drugs discover more about about lobby company profile corporate officers corporate governance board of directors our history 2017 annual report – form 10-k quality notice of annual meeting of shareholders 2017 – proxy statement products products lobby specialty generic products generic faq over the counter (otc) api quality central nervous system (cns) respiratory research research lobby integrated r&d; our focus patient promise pipeline national network of excellence responsibility responsibility lobby social impact positions & policies patient advocacy social impact report multiple chronic conditions media media lobby latest news featured stories social media featured stories social media investors investors lobby news webcasts and presentations corporate governance financial information stock information shareholder information analysts coverage/consensus investor kit careers careers lobby dare to be different our guiding values leadership development working at teva dare to be different search teva jobs teva worldwide stock contact us hebrew follow us: teva in action see what we’re doing and where all news top news sep 4, 2018 teva announces $400 million debt tender offer learn more share top news aug 16, 2018 teva and regeneron announce positive topline phase 3 fasinumab results in patients with chronic pain from osteoarthritis of the knee or hip learn more share top news aug 6, 2018 teva announces updated indication and vial presentation for granix® (tbo-filgrastim) injection in united states learn more share top news aug 2, 2018 teva reports second quarter 2018 financial results learn more share top news jul 17, 2018 teva highlights key milestones achieved in the 2017 social impact report learn more share social impact report highlights infographic learn more featured stories take a closer look at what’s happening at teva all featured stories tapi & biologics update discover more new mumbai r&d; center learn more battling a global epidemic: ncds learn more amplifying the patient voice discover more zoom in on teva creatives learn more social impact at teva our unique perspective on health enables you to live better days specialized in cns & respiratory cutting-edge r&d uncompromising quality the world’s generic leader corporate responsibility this site uses cookies to give you a better browsing experience. by continuing to use this website, you accept our use of these cookies. for more information, see our privacy and cookie notice . about company profile corporate officers corporate governance board of directors our history products specialty generic products generic faq over the counter (otc) api quality research integrated r&d; our focus patient promise pipeline responsibility social impact positions & policies patient advocacy media latest news featured stories social media investors news webcasts and presentations corporate governance financial information stock information shareholder information analysts coverage/consensus investor kit careers dare to be different our guiding values leadership development working at teva follow teva: legal notes data privacy tapi teva supplier code of conduct sitemap © 2015

URL analysis for actavis.be

http://www.tevapharm.com/news/teva_announces_updated_indication_and_vial_presentation_for_granix_tbo_filgrastim_injection_in_united_states_08_18.aspx
http://www.tevapharm.com/corporate_responsibility/social_impact/social_impact_report/
https://twitter.com/share?url=http://www.tevapharm.com/news/teva_announces_400_million_debt_tender_offer_09_18.aspx
http://www.tevapharm.com/teva_worldwide/international_markets/teva_in_china/
http://www.tevapharm.com/teva_worldwide/north_america/
http://www.tevapharm.com/our_products/specialty_products/respiratory/
http://www.tevapharm.com/news/teva_and_regeneron_announce_positive_topline_phase_3_fasinumab_results_in_patients_with_chronic_pain_from_osteoarthritis_of_the_knee_or_hip_08_18.aspx
http://www.tevapharm.com/teva_worldwide/north_america/
http://www.tevapharm.com/teva_worldwide/europe/
http://www.facebook.com/sharer.php?u=http://www.tevapharm.com/news/teva_reports_second_quarter_2018_financial_results_08_18.aspx
http://www.tevapharm.com/research_development/rd_partnerships/patient_safety/
http://www.tevapharm.com/?catid=%7bc09b0f02-d35c-4ca3-9d78-7d50b6c9c1d9%7d
http://www.tevapharm.com/investor_relations/
http://www.tevapharm.com/?catid=%7bacb4607e-b266-4e46-8360-745dd4cab0da%7d
http://www.tevapharm.com/teva_worldwide/north_america/teva_in_canada/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

% .be Whois Server 6.1
%
% The WHOIS service offered by DNS Belgium and the access to the records in the DNS Belgium
% WHOIS database are provided for information purposes only. It allows
% persons to check whether a specific domain name is still available or not
% and to obtain information related to the registration records of
% existing domain names.
%
% DNS Belgium cannot, under any circumstances, be held liable where the stored
% information would prove to be incomplete or inaccurate in any sense.
%
% By submitting a query you agree not to use the information made available
% to:
% - allow, enable or otherwise support the transmission of unsolicited,
% commercial advertising or other solicitations whether via email or otherwise;
% - target advertising in any possible way;
% - to cause nuisance in any possible way to the domain name holders by sending
% messages to them (whether by automated, electronic processes capable of
% enabling high volumes or other possible means).
%
% Without prejudice to the above, it is explicitly forbidden to extract, copy
% and/or use or re-utilise in any form and by any means (electronically or
% not) the whole or a quantitatively or qualitatively substantial part
% of the contents of the WHOIS database without prior and explicit permission
% by DNS Belgium, nor in any attempt thereof, to apply automated, electronic
% processes to DNS Belgium (or its systems).
%
% You agree that any reproduction and/or transmission of data for commercial
% purposes will always be considered as the extraction of a substantial
% part of the content of the WHOIS database.
%
% By submitting the query you agree to abide by this policy and accept that
% DNS Belgium can take measures to limit the use of its whois services in order to
% protect the privacy of its registrants or the integrity of the database.
%

Domain: actavis.be
Status: NOT AVAILABLE
Registered: Tue Jan 13 2009

Registrant:
Not shown, please visit www.dnsbelgium.be for webbased whois.

Registrar Technical Contacts:
Name: Technical Manager
Organisation: Com Laude
Language: en
Phone: +44.2074218250
Fax: +44.8700118187
Email: [email protected]


Registrar:
Name: Nom IQ Ltd COM LAUDE
Website: http://www.comlaude.com

Nameservers:
odinn.medis.is
andromeda.medis.is
ares.medis.is

Keys:

Flags:

Please visit www.dnsbelgium.be for more info.

  REFERRER http://www.domain-registry.nl

  REGISTRAR DNS Belgium

SERVERS

  SERVER be.whois-servers.net

  ARGS actavis.be

  PORT 43

  TYPE domain

DOMAIN

  NAME actavis.be

  STATUS NOT AVAILABLE

  CREATED Tue Jan 13 2009

NSERVER

  ODINN.MEDIS.IS 209.143.183.136

  ANDROMEDA.MEDIS.IS 193.110.132.155

  ARES.MEDIS.IS 213.220.114.10

  WWW.DNSBELGIUM.BE 107.154.249.139

  REGISTERED no

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .